Divis Laboratories Ltd Q4 FY26 Earnings Analysis

- Divi's Laboratories expects steady growth with constant currency growth at around 8.5% to 10% over the near term (Page 13). - Growth will be supported by a broad basket of custom synthesis (CS) products in various patent phases, balancing late life cycle, secondary source, and new product launches (Pages 9 and 13). - Presence of multiple molecules in Phase II and Phase III clinical trials underpins a stable long-term growth trajectory (Page 13). - Expansion of dedicated manufacturing blocks and peptide capacities is ongoing, with commercial scale readiness for new custom synthesis products expected post-2027 (Pages 12 and 17). - Generics segment volume growth remains strong, though value growth is subdued due to pricing pressures; expectation of correction/improvement in generic API pricing is uncertain and depends on market dynamics (Pages 9 and 14). - Nutraceutical business showed growth, contributing ₹706 crores in 9 months, indicating diversification (Page 6).

- Divi's Laboratories aims for consistent double-digit growth, with an 8.5% constant currency growth achieved for 9 months ended December 2025. - Revenue growth is expected to be supported by multiple Custom Synthesis (CS) projects entering commercial volume within the next year. - The company targets improving gross asset turnover ratio back to historical levels of 1.5-1.6 over the next 4-5 years, indicating more efficient capital utilization. - Margins and profitability are expected to improve with a favorable product mix skewed towards higher-margin CS products and ongoing backward integration efforts. - New peptide capacities and innovative technologies (process automation, mechanochemistry, electrochemistry) are expected to further enhance efficiency and profitability. - While short-term generic pricing pressures persist, volume growth and new product launches should sustain earnings growth. - Forward-looking statements reflect confidence in long-term value creation and operational excellence driving future earnings expansion.

- Capex of ₹1,900 crores for FY '26 intimated to SEBI, slightly below initial guidance of ₹2,000 crores. - Capex focus on Unit 1 and Unit 3, especially Unit 3, undergoing multiple design phases. - Future capex plans will be announced to SEBI once a futuristic outlook is finalized, particularly for heavy investments. - Evaluation ongoing for Phase 2 expansion of Kakinada Unit 3 with 4 production blocks, decision pending. - Investments continuing on dedicated custom synthesis (CS) projects; commercialization expected by end of FY 2027. - Backward integration via Unit 3 supporting Units 1 and 2; future API approvals may enable commercial use of Unit 3. - Capex aimed to support capacity expansion, backward integration, and peptide manufacturing capabilities. Overall, strategic investments are focused on capacity expansion, backward integration, and dedicated custom synthesis facilities with timelines extending over next 1-2 years.

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company indicates substantial capital expenditure (capex) underway (₹1,900 to ₹2,000 crores for FY ’26) funded through internal accruals and a strong balance sheet with cash and cash equivalents of ₹3,686 crores as of December 31, 2025. - The management highlights prudent capital allocation and a strong balance sheet to support future growth. - No references were made to new debt or equity issuance during the call or in the provided sections. - Any future capex and investments appear to be planned and disclosed through SEBI intimations as needed, with no mention of external fundraising. Hence, based on the transcript, there is no indication of current or imminent fundraising via debt or equity.

- The company is engaged in several custom synthesis projects, with 3 dedicated molecules currently validated and undergoing regulatory approvals. - Validations for some products are completed, while others are ongoing or planned in the near term. - Commercialization of these products is expected to start around the second half of FY '27, post regulatory approvals. - Production blocks are mostly multipurpose, enabling quick scaling or adaptation for new products as needed. - There is no specific quantitative order backlog shared due to confidentiality agreements with clients. - Capacity expansions and backward integrations are ongoing to support anticipated demand. - The company maintains a healthy volume growth and market share in generics and custom synthesis segments while continuously onboarding new molecules across various lifecycle stages.